153 related articles for article (PubMed ID: 38474205)
1. Pulmonary Adenocarcinoma In Situ and Minimally Invasive Adenocarcinomas in European Patients Have Less
Petterson J; Mustafa D; Bandaru S; Eklund EÄ; Hallqvist A; Sayin VI; Gagné A; Fagman H; Akyürek LM
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474205
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor mutations in adenocarcinoma in situ and minimally invasive adenocarcinoma detected using mutation-specific monoclonal antibodies.
Nakamura H; Koizumi H; Kimura H; Marushima H; Saji H; Takagi M
Lung Cancer; 2016 Sep; 99():143-7. PubMed ID: 27565930
[TBL] [Abstract][Full Text] [Related]
3. Evolution of lung adenocarcinoma from preneoplasia to invasive adenocarcinoma.
Zhu J; Wang W; Xiong Y; Xu S; Chen J; Wen M; Zhao Y; Lei J; Jiang T
Cancer Med; 2023 Mar; 12(5):5545-5557. PubMed ID: 36325966
[TBL] [Abstract][Full Text] [Related]
4. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
5. EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma.
Chalela R; González-García JG; Khilzi K; Curull V; Sánchez-Font A; Longarón R; Rodrigo-Calvo MT; Martín-Ontiyuelo C; Gea J; Bellosillo B
Pathol Oncol Res; 2021; 27():598292. PubMed ID: 34257550
[TBL] [Abstract][Full Text] [Related]
6. Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study.
Ishida H; Shimizu Y; Sakaguchi H; Nitanda H; Kaneko K; Yamazaki N; Yanagihara A; Taguchi R; Sakai F; Yasuda M; Kobayashi K
Lung Cancer; 2019 Mar; 129():16-21. PubMed ID: 30797486
[TBL] [Abstract][Full Text] [Related]
7. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
[TBL] [Abstract][Full Text] [Related]
8. In-depth proteomics reveals the characteristic developmental profiles of early lung adenocarcinoma with epidermal growth factor receptor mutation.
Dai T; Adachi J; Dai Y; Nakano N; Yamato M; Kikuchi S; Usui S; Minami Y; Tomonaga T; Noguchi M; Matsubara D; Sakamoto N
Cancer Med; 2023 May; 12(9):10755-10767. PubMed ID: 37004157
[TBL] [Abstract][Full Text] [Related]
9. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
11. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
12. [Computed tomography findings, clinicopathological features, genetic characteristics and prognosis of
Shen L; Lin J; Wang B; Xu H; Zhao K; Zhang L
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Sep; 39(9):1107-1112. PubMed ID: 31640952
[TBL] [Abstract][Full Text] [Related]
13. Impact of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of stage IA adenocarcinoma of the lung: Correlation between computed tomography images and EGFR and KRAS gene mutations.
Wang T; Zhang T; Han X; Liu XI; Zhou N; Liu Y
Exp Ther Med; 2015 Jun; 9(6):2095-2103. PubMed ID: 26136941
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary adenocarcinoma in situ: analyses of a large series with reference to smoking, driver mutations, and receptor tyrosine kinase pathway activation.
Sato S; Motoi N; Hiramatsu M; Miyauchi E; Ono H; Saito Y; Nagano H; Ninomiya H; Inamura K; Uehara H; Mun M; Sakao Y; Okumura S; Tsuchida M; Ishikawa Y
Am J Surg Pathol; 2015 Jul; 39(7):912-21. PubMed ID: 25970685
[TBL] [Abstract][Full Text] [Related]
15. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
16. Targeted sequencing reveals clonal genetic changes in the progression of early lung neoplasms and paired circulating DNA.
Izumchenko E; Chang X; Brait M; Fertig E; Kagohara LT; Bedi A; Marchionni L; Agrawal N; Ravi R; Jones S; Hoque MO; Westra WH; Sidransky D
Nat Commun; 2015 Sep; 6():8258. PubMed ID: 26374070
[TBL] [Abstract][Full Text] [Related]
17. Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ.
Xu X; Li N; Zhao R; Zhu L; Shao J; Zhang J
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2447-2453. PubMed ID: 28821955
[TBL] [Abstract][Full Text] [Related]
18. Cytomorphologic features of advanced lung adenocarcinomas tested for EGFR and KRAS mutations: a retrospective review of 50 cases.
Marotti JD; Schwab MC; McNulty NJ; Rigas JR; DeLong PA; Memoli VA; Tsongalis GJ; Padmanabhan V
Diagn Cytopathol; 2013 Jan; 41(1):15-21. PubMed ID: 21681971
[TBL] [Abstract][Full Text] [Related]
19. Genetic features of pulmonary adenocarcinoma presenting with ground-glass nodules: the differences between nodules with and without growth.
Kobayashi Y; Mitsudomi T; Sakao Y; Yatabe Y
Ann Oncol; 2015 Jan; 26(1):156-161. PubMed ID: 25361983
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
Villaruz LC; Socinski MA; Abberbock S; Berry LD; Johnson BE; Kwiatkowski DJ; Iafrate AJ; Varella-Garcia M; Franklin WA; Camidge DR; Sequist LV; Haura EB; Ladanyi M; Kurland BF; Kugler K; Minna JD; Bunn PA; Kris MG
Cancer; 2015 Feb; 121(3):448-56. PubMed ID: 25273224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
